Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy.
about
Cooperation between integrin alphavbeta3 and VEGFR2 in angiogenesisOcular Complications of Diabetes and Therapeutic ApproachesAlternative pathways in the development of diabetic retinopathy: the renin-angiotensin and kallikrein-kinin systemsQuercetin-4'-O-β-D-glucopyranoside (QODG) inhibits angiogenesis by suppressing VEGFR2-mediated signaling in zebrafish and endothelial cellsPlacental growth factor contributes to micro-vascular abnormalization and blood-retinal barrier breakdown in diabetic retinopathySystemic propranolol reduces b-wave amplitude in the ERG and increases IGF-1 receptor phosphorylation in rat retinaAngiomyogenesis for myocardial repair.Proliferative diabetic retinopathy: predictive and preventive measures at hypoxia induced retinal changes.Galectin-1 expression imprints a neurovascular phenotype in proliferative retinopathies and delineates responses to anti-VEGFProfile of lipid and protein autacoids in diabetic vitreous correlates with the progression of diabetic retinopathy.Apelin in epiretinal membranes of patients with proliferative diabetic retinopathy.Inhibition of protein kinase CK2 suppresses angiogenesis and hematopoietic stem cell recruitment to retinal neovascularization sites.The retinal pigment epithelium: something more than a constituent of the blood-retinal barrier--implications for the pathogenesis of diabetic retinopathy.Iron overload in diabetic retinopathy: a cause or a consequence of impaired mechanisms?Maternal immune system adaptation to pregnancy--a potential influence on the course of diabetic retinopathy.Antiangiogenic therapy for ischemic retinopathies.Vitreous and plasma VEGF levels as predictive factors in the progression of proliferative diabetic retinopathy after vitrectomyBevacizumab therapy normalizes the pathological intraocular environment beyond neutralizing VEGF.Usefulness of the vitreous fluid analysis in the translational research of diabetic retinopathyHbA1c variability is associated with an increased risk of retinopathy requiring laser treatment in type 1 diabetes.Choosing preclinical study models of diabetic retinopathy: key problems for considerationInverse association between high blood 25-hydroxyvitamin D levels and diabetic retinopathy in a representative Korean populationElevation of serum apelin-13 associated with proliferative diabetic retinopathy in type 2 diabetic patients.The role of apelin in the retina of diabetic rats.Combinatorial regulation of endothelial gene expression by ets and forkhead transcription factorsTranscriptional control of endothelial cell development.The α7-nicotinic acetylcholine receptor and MMP-2/-9 pathway mediate the proangiogenic effect of nicotine in human retinal endothelial cells.Fenofibric acid reduces fibronectin and collagen type IV overexpression in human retinal pigment epithelial cells grown in conditions mimicking the diabetic milieu: functional implications in retinal permeability.Vascular endothelial growth factor in anterior chamber liquid patients with diabetic retinopathy, cataract and neovascular glaucomaHigh prevalence of lower extremity peripheral artery disease in type 2 diabetes patients with proliferative diabetic retinopathy.Evaluation of anti-HIF and anti-angiogenic properties of honokiol for the treatment of ocular neovascular diseases.Photocoagulation of human retinal pigment epithelium in vitro: unravelling the effects on ARPE-19 by transcriptomics and proteomics.Effects of Selected Anionic β-Cyclodextrins on Persistence of Blood Glucose Lowering by Insulin Glargine after Subcutaneous Injection to Rats.Nanoengineering of therapeutics for retinal vascular disease.The relationship between microvascular complications and vitamin D deficiency in type 2 diabetes mellitusIntravitreal Topotecan Inhibits Laser-induced Choroidal Neovascularization in a Rat Model.Activation of AMP-activated protein kinase inhibits the proliferation of human endothelial cells.Prevention of VEGF-induced growth and tube formation in human retinal endothelial cells by aldose reductase inhibitionTMP prevents retinal neovascularization and imparts neuroprotection in an oxygen-induced retinopathy model.Therapeutic potential of a monoclonal antibody blocking the Wnt pathway in diabetic retinopathy
P2860
Q24318607-014D73FD-F5C5-4587-BB99-6CD9FFAE330AQ26749412-2027E2D8-3A43-4F5E-9F56-92E8E355AF1FQ27025635-41CAFD08-CB98-45D5-919C-5C968C0E910FQ28480617-55495814-05E9-40FE-94CB-11B095ACA099Q28565180-3616CBB3-36C1-4D76-BE68-C08716E9463CQ28854271-0EF5093A-B640-4DFA-AEA9-073929F1214AQ30480151-DFA4ADFA-A2F3-438C-8A7B-7C6AC2492DDDQ31107603-951715BD-88E2-4BD9-9975-8FC985ABF92AQ33779141-07FC652B-E04F-4E0D-BE5C-ACA46C6E2078Q33930304-73F64CF1-0016-47AB-A505-AE244351152DQ33990716-231BA02C-1AD0-449C-9399-388DF245CB89Q34034867-C35DBA07-6EA4-4092-B68C-74F6F64BBDD5Q34100527-10214B91-A7E2-4265-8AA5-4F8B5AEF6535Q34109492-AA3B2C9A-2E0B-413B-AB5C-9F2C23D55094Q34273776-011D38B0-437D-43D5-A6A6-115C626686D6Q34295974-7A2752D8-C47E-49E1-9646-57213BD93D5DQ34352379-016BCBBC-0BFC-46DB-A355-1A89232CF8D1Q34364080-E9610C25-ECDC-4D56-B0FD-F4DC2C98002AQ34426246-C62D6B27-2777-4925-8C59-230DD5311BF9Q34546548-7E1A5DBF-EF4A-4198-9459-A8A92C075C82Q34564352-81F8A37D-DA8F-416E-94C6-DD3CE83B2943Q34655098-ADE1EEE7-C436-413C-83E9-AAE9C0F6C571Q34735799-9B0ADEEA-7971-4522-A99F-322A6299903EQ34854449-0D70A213-E9CD-4B9E-AF6C-D9EA20AD429BQ34900031-BC6DE963-6D7F-4700-A267-B981EA5F82ADQ34944977-CB1D673E-DF2A-4C23-AF3C-A817545915E2Q35221001-423B3FC9-F374-4614-9287-6686C4D9AB2EQ35221085-A0F33954-5C9D-44B7-B3B7-1A860AB5E610Q35227644-62A206F3-5343-476B-9A65-ADE2FE58B525Q35231784-85A89327-4213-4FCC-A2CD-448CA958A94EQ35448249-9B0A8A9A-725B-4FA8-B995-577D62044AF6Q35545540-8AA83B31-E488-4E7C-88E7-80422E5C0BD4Q35609223-1D577777-2794-448A-A453-0F9E59A2DE62Q35645705-9823CA37-AD9A-4BE8-AE39-D98386B60F63Q35673714-12FF1D17-B4FA-41E5-A1E1-C07972957797Q35884935-56A350A6-9D94-48FF-AC1D-FCE9AC388D25Q36174159-EE0D73C5-31B6-4413-A56F-BD169B24F115Q36209915-9A2FEEC6-37FF-444D-9D1B-3DC6EED0BBB1Q36232684-E6E91057-3AB6-4BC0-912A-FA4260F44214Q36339514-C39718F8-88B1-4695-A69F-167CC88483F9
P2860
Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy.
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy.
@ast
Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy.
@en
Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy.
@nl
type
label
Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy.
@ast
Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy.
@en
Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy.
@nl
prefLabel
Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy.
@ast
Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy.
@en
Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy.
@nl
P2093
P1476
Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy
@en
P2093
Cristina Hernández
Esther Carrasco
Rafael Simó
P356
10.2174/157339906775473671
P577
2006-02-01T00:00:00Z